Showing 3181-3190 of 3415 results for "".
- FDA Warns that Biotin May Interfere with Lab Test Resultshttps://practicaldermatology.com/news/fda-warns-that-biotin-may-interfere-with-lab-test-results/2457961/Biotin may significantly interfere with certain lab tests and cause "clinically significant incorrect lab test results," the US Food and Drug Administration warns. At least 1 death has been related to biotin interference with laboratory results, FDA officials wrote in a Saf
- Psoriasis Severity Linked to Diabetes Riskhttps://practicaldermatology.com/news/psoriasis-severity-linked-to-diabetes-risk/2457970/Psoriasis patients are more likely to develop Type 2 diabetes than their psoriasis-free counterparts, and this risk increases dramatically based on the severity of the disease, according to researchers from the Perelman School of Medicine at the University of
- Isdin Introduces Two New Productshttps://practicaldermatology.com/news/isdin-introduces-two-new-products/2457977/ISDIN is rolling out ISDIN Age Contour plus a new shade in their ISDINCEUTICS Skin Drops collection. ISDIN AGE CONTOUR is a triple-action face and neck cream that aims to reduce jawline sagging and glycation in the skin as well as protect&nb
- FDA Accepts Ortho Dermatologic's NDA for Novel Plaque Psoriasis Treatment, IDP-118https://practicaldermatology.com/news/fda-accepts-ortho-dermatologics-nda-for-novel-plaque-psoriasis-treatment-idp-118/2457988/The US Food and Drug Administration has accepted Ortho Dermatologic's New Drug Application (NDA) for IDP-118 (halobetasol propionate and tazarotene) lotion, an investigational topical treatment for plaque psoriasis. The PDUFA action date i
- Meet Thermage's New FLX Systemhttps://practicaldermatology.com/news/meet-thermages-new-flxtm-system/2458026/The US Food and Drug Administration granted 510(K) clearance to Solta Medical’s new Thermage FLXTM System for smoothing skin on the face, eyes, and body. The Thermage FLX features a new optimized energy delivery algorithm, know
- Sculpsure Cleared to Treat Double Chinshttps://practicaldermatology.com/news/sculpsure-cleared-to-treat-double-chins/2458036/Cynosure's SculpSure® is now cleared for submental fat reduction. The U.S. Food and Drug Administration (FDA) granted an expanded FDA 510(k) clearance for this area, Hologic, Inc. reports.
- New Data: Aclaris' A-101 40% Safely Banishes Facial SK Lesionshttps://practicaldermatology.com/news/new-data-aclaris-a-101-40-safely-banishes-facial-sk-lesions/2458044/Good news for Aclaris. New data suggest that their drug candidate A-101 40 percent may be an appealing option to remove seborrheic keratosis (SK) lesions in highly visible areas, such as the face, with minimal risk of s
- Allergan Adds Coolsculpting, Other Bells and Whistles to Brilliant Distinctions® Patient Loyalty Programhttps://practicaldermatology.com/news/allergan-adds-coolsculpting-other-bells-and-whistles-to-brilliant-distinctions-patient-loyalty-program/2458056/Allergan is launching the next generation of its U.S.-based Brilliant Distinctions® program. The new offering incorporates digital innovation to enhance the consumer experience and drive increased member engagement. In addition
- FDA Accepts NDAs for Review of Binimetinib And Encorafenib for Advanced BRAF-mutant Melanomahttps://practicaldermatology.com/news/fda-accepts-ndas-for-review-of-binimetinib-and-encorafenib-for-advanced-braf-mutant-melanoma/2458058/The FDA has accepted Array BioPharma's New Drug Applications (NDAs) to support use of the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily (COMBO450) for the treatment of patients with BRAF-mutant advanced, unresectable or metastatic melanoma. The FDA se
- Dermira Presents New Data on Late-Stage Programs at European Dermatology Congresshttps://practicaldermatology.com/news/dermira-presents-new-data-on-late-stage-programs-at-european-dermatology-congress/2458066/Dermira, Inc. will present data from its glycopyrronium tosylate (formerly DRM04) and Cimzia (certolizumab pegol) Phase 3 clinical programs in poster sessions at the 26th European Academy of Dermatology and Venereology (EADV) Congress, taking place in Geneva, Switzerland, September 13&